GlassScriptPhysician profile
Elizabeth Mathew
NPI 1346589132
$5,521.70
in general payments reported to CMS, 2019-2025
25 companies · $642 in 2025
The $642 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,814 · 2020: $999 · 2021: $337 · 2022: $649 · 2023: $674 · 2024: $407 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,547 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,546.98 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $724.34 | 2019-2024 | |
| Janssen Biotech, INC. | $683.76 | 2019-2025 | Tremfya |
| Amgen INC. | $649.78 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $623.94 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $519.50 | 2019-2025 | Benlysta |
| Abbvie INC. | $514.67 | 2020-2025 | |
| Mallinckrodt Enterprises LLC | $377.39 | 2019 | |
| Novartis Pharmaceuticals Corporation | $320.28 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.01 | 2019-2024 | Ofev, Cyltezo |
| Vifor Pharma, INC. | $126.65 | 2019-2020 | |
| Lilly USA, LLC | $126.63 | 2021-2025 | Taltz |
| Sobi, INC | $97.93 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $82.12 | 2021-2025 | Saphnelo |
| Genentech USA, INC. | $71.21 | 2019-2025 | Actemra |
| Medexus Pharma, INC. | $60.72 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $51.49 | 2019 | |
| Janssen Scientific Affairs, LLC | $51.33 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $50.78 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $50.77 | 2020 | |
| Genzyme Corporation | $49.90 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $42.61 | 2025 | Purified Cortrophin Gel |
| Fidia Pharma USA INC. | $28.09 | 2023 | Hymovis, Triluron |
| Alexion Pharmaceuticals, INC. | $26.24 | 2025 | Strensiq |
| Lundbeck LLC | $12.27 | 2019 | |
| Merck Sharp & Dohme LLC | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.